NLS Biotech News

Lifelong learning: Transform your business with technological convergence

If you want to position yourself as a strategic force within your organization, someone who drives both growth and sustainability, the ELPIS – Lead the Biorevolution across Life Science course is definitely for you.

Agreement – June 2, 2026

Camurus and Lilly sign deal on long-acting incretin therapies

Camurus has entered a global collaboration and license agreement with Eli Lilly and Company to develop long-acting incretin-based therapies for cardiometabolic diseases using its FluidCrystal technology platform.

Optimize your production lines before they slow down your operations

In the pharmaceutical industry, poor production line planning can lead to delays, capacity losses, quality risks, and additional costs. What if you could identify production constraints before they impact your performance?

Agreement – May 19, 2026

Hansa Biopharma in EUR 115 million licensing agreement

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

Biotech Business – May 11, 2026

FDA extends sBLA review of Leqembi Iqlik

BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.

Clinical trials

Clinical Trials – May 25, 2026

Sobi announces positive Phase 3 results

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Clinical Trials – May 20, 2026

Oncopeptides secures regulatory approval to start Window-of-Opportunity study

Oncopeptides’ clinical trial application for the “Window-of-Opportunity” (WoO) study in glioblastoma has been formally approved in Norway.

Clinical Trials – May 19, 2026

Orexo announces positive outcome from an in-vivo study

Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.

Clinical Trials – May 12, 2026

AnaCardio announces Phase 1b/2a results

AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).

Clinical Trials – May 6, 2026

Spago Nanomedical reports phase I/IIa study data

The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.

Clinical Trials – April 24, 2026

Takeda reports additional Phase 3 clinical insights on TAK-279

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).

Clinical Trials – April 22, 2026

Hemispherian initiates Phase 1/2a clinical trial

The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

Clinical Trials – April 22, 2026

Lytix Biopharma announces Phase II results

The company has announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy.

Clinical Trials – April 21, 2026

Novo Nordisk’s etavopivat met both co-primary endpoints in phase 3 trial

The company has announced the topline results from HIBISCUS, a phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD).

Clinical Trials – April 19, 2026

Evaxion’s AI-Immunology platform demonstrates 86% vaccine target precision

Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his new company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech Business - June 4, 2026

Haga Bioscience raises USD 2.3 million

The Swedish spatial biology startup Haga Bioscience has closed a USD 2.3 million oversubscribed seed financing round bringing total funding, including pre-seed financing, to approximately USD 3 million.

Agreement - May 26, 2026

Oncopeptides signs agreement with Salus

The agreement for distribution and commercialization of Pepaxti in Central and Eastern Europe addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.

Biotech Business - May 11, 2026

Oncopeptides to submit type II variation to expand Pepaxti label

Oncopeptides has announced its intention to submit a Type II variation application to the European Medicines Agency (EMA).

Biotech Business - May 11, 2026

Diamyd Medical provides business update

Diamyd Medical has announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.

Biotech Award - May 11, 2026

These are the winners of the Biotech Stars Awards

The Finnish Bioindustries Biotech Stars Awards were presented at the Made by Cells Biotech Forum on 29 April 2026 at Hanaholmen, Espoo, as part of the celebrations marking the 20th anniversary of Finnish Bioindustries.

Biotech Business - May 6, 2026

NextCell and FUJIFILM Biosciences launch commercial platform

The two companies have announced a global commercial launch resulting from their strategic collaboration.

View more Loading ...

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.